Arrowhead Pharmaceuticals (ARWR) EPS (Basic) (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly EPS (Basic) came in at -$0.97 in Q1 2026, down 135.02% YoY from $2.76 in Q1 2025, and down 568.72% on a QoQ basis from $0.21 in Q4 2025.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) EPS (Basic) (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of EPS (Basic) data on file, last reported at -$0.97 in Q1 2026.
- Quarterly EPS (Basic) fell 135.02% year-over-year to -$0.97 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.91 (down 64.62% YoY) and the FY2025 annual result came in at $0.23, up 104.42% from the prior year.
- EPS (Basic) retreated to -$0.97 in Q1 2026, from $0.21 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $2.76 in Q1 2025 to a low of -$1.45 in Q3 2024.
- A 5-year average of -$0.51 and a median of -$0.97 in 2026 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2024 — EPS (Basic) sank 330.66% — and 2025, when it jumped 367.78%.
- Tracing ARWR's EPS (Basic) over 5 years: stood at -$0.39 in 2022, then slumped by 219.76% to -$1.26 in 2023, then dropped by 11.36% to -$1.4 in 2024, then jumped by 114.68% to $0.21 in 2025, then tumbled by 568.72% to -$0.97 in 2026.
- The last three EPS (Basic) figures came in at -$0.97 (Q1 2026), $0.21 (Q4 2025), and $0.12 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | -1.25 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.25 |
| Mar 31, 2026 | -0.97 |
| Dec 31, 2025 | 0.21 |
| Sep 30, 2025 | 0.12 |
| Jun 30, 2025 | -1.28 |
| Mar 31, 2025 | 2.76 |
| Dec 31, 2024 | -1.40 |
| Sep 30, 2024 | -1.45 |
| Jun 30, 2024 | -1.40 |
| Mar 31, 2024 | -1.03 |
| Dec 31, 2023 | -1.26 |
| Sep 30, 2023 | -1.04 |
| Jun 30, 2023 | -0.97 |
| Mar 31, 2023 | 0.45 |
| Dec 31, 2022 | -0.39 |
| Sep 30, 2022 | -0.82 |
| Jun 30, 2022 | -0.68 |
| Mar 31, 2022 | 0.42 |
| Dec 31, 2021 | -0.60 |
| Sep 30, 2021 | -0.61 |